Axovant Sciences has selected French CDMO Yposkesi as a strategic partner to help bring its neurologic and neuromuscular gene therapy candidates through the clinic.
Contract development and manufacturing organization (CDMO) Yposkesi will utilize its adeno-associated virus (AAV) and lentiviral vector production capabilities to service the strategic agreement with Axovant.
Swiss biotech Axovant has a pipeline of gene therapies targeting neurological and neuromuscular diseases.
Financial details have not been divulged, but Alain Lamproye, CEO of Yposkesi, said it is a straight forward contract deal.
â€śWe will provide Axovant access to one of our several cGMP manufacturing suites.Â The agreement concerns the next several years,â€ť he told this publication. â€śYposkesi will provide the capacity, including cleanrooms, equipment and the required personnel.â€ť
Yposkesi has four cGMP manufacturing suites and two fill & finish suitesat its site located about 20km south of Paris. The firm has current capacity of 35 batches per year.
â€śYposkesi has a fully equipped cGMP manufacturing plant, able to handle multiple types of processes for the production of viral vectors.Â There is no need to invest into specific equipment and/or hire additional staff [to service this deal.â€ť
However, the firm is adding a 10,000 m2 facility comprising of two independent suites equipped with 1,000 L single-use bioreactors, commissioned for Q3 2021.
Talking to us in July, Lamproye said the expansion is a necessary response to the high demand for viral vector supply, which is â€śhigher than the current global capacity of the CMOs.â€ť